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Reliability of chronic allograft nephropathy diagnosis in se- different renal compartments [3]. Histological confirma-
quential protocol biopsies. tion of CAN in patients with slowly deteriorating renal
Background. Chronic allograft nephropathy (CAN) prog- function usually shows that the degree of renal scarringresses rapidly during the first few months and slowly thereafter.
is advanced, probably beyond the threshold of reversibil-Although the presence of CAN in protocol renal biopsies is a
ity. Accordingly, it seems unreasonable to expect thatpredictor of outcome, the reliability of this diagnosis according
to Banff criteria has not been characterized. at this stage of scarring a therapeutic maneuver may
Methods. Renal lesions were evaluated according to the significantly slow renal function deterioration [4].
Banff criteria in sequential protocol biopsies performed at 4 Some centers have performed protocol biopsies as an
and 14 months in 310 biopsies obtained from 155 patients.
attempt to diagnose CAN at an earlier stage. In theseResults. CAN progressed from 40 to 53% (P  0.001) while
studies, the timing of histological evaluation has beenserum creatinine remained stable (146  44 vs. 147  48
mol/L, P  NS). Graft survival in patients with and without targeted during the first two years after transplant. Nev-
CAN in the first biopsy was 74 versus 91% (P  0.05), and in ertheless, CAN was a frequent finding in all of the stud-
the second biopsy 75 versus 94% (P  0.05). In 54 patients ies, ranging between 25 and 70% [5–9]. In studies of
(35%) no CAN was present in both biopsies, 39 (25%) showed
sequential protocol biopsies it has been observed thatprogression to CAN, 19 (12%) showed regression of CAN,
the incidence and severity of CAN is time dependentand 43 (28%) showed CAN in both biopsies. Graft survival
was: 100%, 81.6%, 82.6% and 69.4%, respectively (P  0.01). [10–14]. Furthermore, in all of the previously mentioned
Assuming that CAN does not regress and sampling error is studies there is agreement that the presence of CAN in
normally distributed, we estimated that 25% of biopsies cannot stable grafts is an independent predictor of renal allograft
be properly classified.
outcome. Taken together, these results suggest that theConclusions. The increase in the incidence of CAN between
presence of scarring in protocol biopsies could be consid-the 4th and 14th month is lower than the proportion of misclassi-
fied biopsies. Thus, monitoring the progression of CAN by ered as a primary efficacy variable in a hypothetical clini-
means of two sequential biopsies at 4 and 14 months is inaccu- cal trial aimed to prevent CAN [15, 16]. However, neither
rate. We suggest that progression of scarring be monitored by the accuracy of the diagnosis of CAN in sequential proto-
means of a donor and a protocol biopsy performed during the
col biopsies nor the ideal timing of biopsies to detectfirst year evaluated with a quantitative approach.
patients at risk of graft failure have been properly evalu-
ated.
The present study analyzed the evolution of renal le-Chronic allograft nephropathy (CAN) is the most
sions evaluated according to the Banff schema in twocommon cause of late renal allograft failure [1] clinically
sequential protocol biopsies performed at 4th and 14thcharacterized by a slow deterioration of renal function
months after transplantation.[2]. Histologically, CAN is defined according to the Banff
schema, a classification system that relies on the semi-
quantitative evaluation of chronic renal damage in the METHODS
Patients
Since June 1988 a prospective study of protocol renalKey words: Banff criteria, transplantation, graft outcome, renal lesions,
kidney graft, classification of biopsies. allograft biopsies has been conducted in our center
[7, 15]. A first protocol renal allograft biopsy was per-Received for publication May 30, 2001
formed at approximately 3 months in patients who gaveand in revised form September 10, 2001
Accepted for publication September 25, 2001 their informed consent and fulfilled the following crite-
ria: (a) serum creatinine  300 mol/L; (b) proteinuria 2002 by the International Society of Nephrology
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1 g/24 h; and (c) stable renal function, defined as vari- embedded in paraffin, cut into 4-m sections and stained
ability of serum creatinine of less than 15% during two with hematoxylin and eosin, periodic acid-Schiff, Mas-
weeks before and after biopsy. A second protocol biopsy son’s trichrome and silver methenamine. Renal lesions
was performed at approximately one year of follow-up were graded and diagnosed according to the 1997 Banff
regardless of serum creatinine or proteinuria. For the schema by two observers in the absence of any clinical
present study, only patients biopsied until December information [3]. Protocol biopsies were not available to
1996 were included. clinicians and consequently were not employed to make
any clinical decisions.
Definition of clinical variables
StatisticsThe following variables were evaluated in each patient
at the time of surgery: donor type (heart beating or Results are expressed as the mean  standard devia-
non-heart beating), age and sex of the donor and the tion. Comparison between paired data was performed
recipient, presence of hepatitis C virus antibodies, etiol- by means of Chi square test, Wilcoxon test and t test for
ogy of end-stage renal disease, time on dialysis, last panel repeated measures. Comparison between unpaired data
reactive antibodies, number of HLA mismatches, and was performed by means of the chi-square test, Student
cold ischemia time (CIT). After surgery, the presence t test, Mann-Whitney U test, and the analysis of variance
of delayed graft function and acute rejection were evalu- (ANOVA) with the Scheffe´ test for individual compari-
ated. At the time of protocol biopsies and during follow- sons. Spearman’s correlation was employed to analyze
up, serum creatinine, calculated glomerular filtration rate the relationship between ordinal parameters. Kaplan-
(GFR) by means of the Cockroft-Gault formula [17], Meier analysis was used to calculate graft survival and
proteinuria, blood pressure, cyclosporine (CsA) dose the Mantel-Cox log-rank test was used to compare sur-
and CsA levels were recorded. Mean CsA level and vival between groups. For survival analysis, patients dy-
dose at the time of the first biopsy were calculated as a ing with a functioning graft were censored. All P values
weighted-time mean from CsA levels and doses at one were two-tailed and a P value 0.05 was considered
week, two weeks, one month, two months, and CsA level significant.
and dose at the time of the first biopsy. Mean CsA level
and dose between biopsies were calculated from CsA
RESULTSlevels and doses at four, six, 12 months, and CsA level
and dose at the time of the second biopsy. Patients
Total number of HLA mismatches was calculated as
During the study period a first and second protocolthe addition of the number of mismatches in the A,
biopsy were done in 191 patients. Sufficient tissue forB and DR loci. Delayed graft function was defined as
histological evaluation was not obtained in 17 first andhemodialysis requirements during the first week after
19 second biopsies. Thus, 310 biopsies performed in 155surgery once accelerated or hyperacute rejection, vascu-
patients were included. Follow-up time ranged betweenlar complications and urinary tract obstruction were
5 and 12 years. Demographic characteristics of patientsruled out. The diagnosis of acute rejection was defined
are summarized in Table 1.as an acute rise of serum creatinine 30% that re-
sponded to antirejection therapy. A diagnostic biopsy at Biopsies and sampling adequacy
the time of serum creatinine worsening was done in 75%
The first biopsy was performed at approximately 4of patients. Hypertension before and after transplanta-
months (113 46 days) and the second biopsy was donetion was defined as a mean arterial pressure107 mm Hg
just after the first year (435  70 days). Mean number(blood pressure of 140/90 mm Hg) and/or the require-
of glomeruli was 12  7 and 11  7, respectively. Allment of antihypertensive drugs. During this period of
biopsies contained at least one glomerular and one arte-time, different combinations of immunosuppressive
rial section and sample size distribution according todrugs have been employed: (a) CsA and prednisone (N
1997 Banff criteria in the 310 biopsies was: 173 (55.8%)10), (b) concomitant induction therapy with antilympho-
biopsies were adequate (10 glomeruli, 2 arteries), 72cytic antibodies, CsA and prednisone (N 87); (c) triple
(23.2%) biopsies represented minimum sample ade-standard regimen with CsA, azathioprine and predni-
quacy (between 7 and 9 glomeruli and at least one arte-sone (N 18); (d) triple regimen with CsA, mycopheno-
rial section) and 65 (21.0%) biopsies were inadequatelate mofetil and prednisone (N  35); and (e) induction
(between 1 and 6 glomeruli and at least one arterialtherapy with antilymphocytic antibodies, mycophenolate
section).mofetil and prednisone (N  5) [15].
Temporal evolution of renal lesionsBiopsies
During this period of time no significant modificationBiopsies were performed and processed for routine
light microscopy as previously described [7]. Tissue was in the intensity of acute lesions was observed while the
Sero´n et al: Chronic allograft nephropathy in serial biopsies 729
Table 3. Evolution of clinical parametersTable 1. Patient characteristics
Variable Mean  SD Range First Second
protocol protocol
Donor age years 3517 6–76 biopsy biopsy P
Donor sex male/female 107/48
HBD/NHBD 140/15 Creatinine lmol/l 14644 14748 NS
Calculated GFR mL/min/1.73 m2 5314 5414 NSRecipient age years 4313 15–71
Recipient sex male/female 94/61 Mean arterial pressure mm Hg 10112 10412 NS
Proteinuria g/24 hr 0.310.21 0.380.52 0.044Number of transplant 1st/2nd/3rd 138/16/1
HCV positive/negative 23/132 CsA dose mg/kg/day 5.42.3 4.11.5 0.0001
CsA level ng/mL 21674 15948 0.0001Etiology of end-stage renal disease





Table 4. Concordance between the diagnosis of chronic allograftTime on dialysis months 2930 0–195
Last PRA % 818 0–100 nephropathy (CAN) in the first and second biopsies (P  0.01)
HLA ABDR mismatches 2.91.1 0–5
2nd biopsy 2nd biopsyCold ischemia time hours 246 10–46
without CAN with CANDelayed graft function yes/no 28/127
Acute rejection yes/no 32/123 1st biopsy without CAN 54 (34.8%) 39 (25.2%)
1st biopsy with CAN 19 (12.2%) 43 (27.7%)Abbreviations are: HBD, heart-beating donor; NHBD, non-heart beating
donor; HCV, hepatitis C virus antibodies; APKD, adult polycystic kidney disease;
PRA, panel reactive antibodies.
correlation was found between the degree of acute le-
Table 2. Evolution of histologic lesions sions in the first biopsy and chronic lesions in the second
biopsy. There was a positive correlation between ci-scoreFirst protocol Second protocol
Lesion type biopsy biopsy P and ct-score in the first and cv-score in the second biopsy
(rho0.23, P  0.004, and rho0.21, P  0.007, respec-g 0.100.34 0.130.46 NS
i 0.690.73 0.580.64 NS tively).
t 0.441.0 0.300.50 NS
v 0 0 NS Temporal evolution of histologicalah 0.170.4 0.210.48 NS
diagnostic categoriescg 0.170.38 0.350.56 0.0036
ci 0.460.61 0.730.77 0.0003 Histological diagnoses according to the Banff criteriact 0.460.63 0.690.75 0.0028
in the first protocol biopsy were: normal (N  66), bor-cv 0.060.27 0.160.50 0.035
derline (N  24), acute rejection (N  3), CAN (N Abbreviations are: g, glomerulitis; i, interstitial infiltrate; t, tubulitis; v, vasculi-
tis; ah, arteriolar hyalinosis; cg, chronic glomeruli; ci, chronic interstitium; ct, 38), CAN associated with borderline changes (N  20)
chronic tubuli; cv, chronic vascular.
and CAN associated with acute rejection (N 4). Histo-
logical diagnoses in the second protocol biopsy were:
normal (N  64), borderline (N  8), acute rejection
(N 1), CAN (N 53), CAN associated with borderlineseverity of chronic lesions increased in all renal compart-
changes (N 28), and CAN associated with acute rejec-ments (Table 2). Despite progression of renal scarring,
tion (N  1). Thus, in the first protocol biopsy CAN wasserum creatinine and calculated GFR as well as mean
diagnosed in 62 of 155 (40.0%) patients and in the secondarterial pressure at the time of the first and second proto-
protocol biopsy in 82 of 155 (52.9%) patients (P 0.001).col biopsies remained unchanged. A significant but slight
Not only the proportion but also the severity of CANincrease of proteinuria was observed. According to usual
increased in the second biopsy. Grading of CAN in theclinical practice, CsA doses and CsA levels were lower
at the time of the second protocol biopsy (Table 3). first was: absent in 93 (60.0%) patients, mild in 53
(34.2%), moderate in 9 (5.8%), and no cases showedTo study the degree of correlation between Banff
scores in the first and second biopsies, a matrix correla- severe CAN. In the second biopsy CAN was: absent in
73 (47.1%), mild in 54 (34.8%), moderate in 27 (17.4%),tion between Banff scores in both biopsies was built.
The following significant positive correlations were ob- and severe in 1 (0.6%; P  0.01).
A 2  2 contingency table in which the histologicalserved: g-score in the first and second biopsy (rho 
0.20, P  0.01), i-score in the first and second biopsy diagnosis was summarized as presence or absence of
CAN was employed to study the concordance of the(rho  0.31, P  0.001), ah-score in the first and second
biopsy (rho  0.18, P  0.03), ci-score in the first and diagnosis of CAN in both biopsies (Table 4). In 97 pa-
tients (62.5%) there was agreement in the diagnosis ob-second biopsy (r  0.30, P  0.0002) and ct-score in the
first and second biopsy (rho  0.28, P  0.004). No tained in both sequential biopsies. In 39 patients (25.2%)
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Table 5. Evolution of CAN in patients with two biopsies containing presence of CAN in the second biopsy in patients with
7 glomeruli (minimum sample adequacy in both biopsies) and
a first biopsy not showing CAN or the increase in thein patients with at least one biopsy containing 7 glomeruli
(indequate sampling) (P  NS) CAN grade between the first and second biopsy. The
degree of chronic lesions in the first biopsy was lower
7 glomeruli 7 glomeruli
in patients who progressed. Mean CsA level until the
Both biopsies without CAN 34 (35.1%) 20 (34.4%)
first biopsy was similar in both groups while the meanProgression to CAN 22 (22.6%) 17 (30.9%)
Regression of CAN 12 (12.4%) 7 (12.1%) CsA level between the first and second biopsies was
Both biopsies with CAN 29 (29.9%) 14 (24.1%) lower in patients who progressed. However, the CsA
Total 97 58 dose until the first biopsy and between biopsies was simi-
lar in both groups (Table 7). None of the following vari-
ables was different between the no progression and pro-
gression groups: donor age (35  18 vs. 37  15 years)
not showing CAN in the first protocol biopsy, CAN was
and sex (29 vs. 35% females), recipient age (44  14 vs.
diagnosed in the second. In 19 patients (12.2%) CAN
43  12 years) and sex (37 vs. 43% females), last panelwas diagnosed in the first biopsy but not in the second.
reactivity antibodies (6  20 vs. 10  20%), number ofIn the group of patients not showing CAN in the first
HLA mismatches (2.8  1.1 vs. 2.9 1.0), cold ischemiabiopsy, 27 patients progressed to CAN grade I and 12
time (24 7 vs. 23 6 hours), the proportion of patientspatients progressed to CAN grade II or III. On the con-
treated with mycophenolate mofetil (25 vs. 27%), de-trary, all but one of the 19 patients who apparently re-
layed graft function (19 vs 16%), acute rejection (21 vs.gressed were diagnosed of CAN grade I in the first
20%), serum creatinine (144  41 vs. 148  49 mol/L),biopsy.
calculated GFR (54  14 vs. 52  14 mL/min/1.73 m2),
mean arterial blood pressure (101  11 vs. 102  14Sample size adequacy and diagnosis of CAN
mm Hg) or proteinuria (0.28  0.19 vs. 0.32  0.21 g/day)To evaluate whether apparent regression of CAN in
at the time of the first biopsy.the second biopsy is due to inadequate sampling, the
concordance of the diagnosis of CAN was studied in Prediction of graft survival
patients with at least 7 glomeruli (minimum sample ade-
In order to study which timing of protocol biopsy al-quacy) in both biopsies and in patients with at least one
lowed a better prediction of outcome, graft survival ac-biopsy containing7 glomeruli (inadequate sample). As
cording to the presence or absence of CAN in the firstshown in Table 5, evolution of CAN was not different
and second protocol biopsies was studied separately byin both groups.
means of Kaplan-Meier analysis. Graft survival in pa-
Concordance of the diagnosis of CAN and outcome tients with and without CAN was 74 and 91% in the first
biopsy (P  0.05) and 75 and 94% in the second biopsyTo evaluate whether apparent regression of CAN in
(P  0.05).a proportion of patients represents the inaccuracy of the
diagnostic criteria or a real regression of chronic lesions,
serum creatinine, proteinuria at the time of first and DISCUSSION
second protocol biopsies and renal allograft survival
The present study shows that chronic renal allograftwere compared in the four previously mentioned groups.
lesions progress between the 4th and 14th month, whileAs shown in Table 6, serum creatinine and proteinuria
serum creatinine, calculated GFR and arterial pressurevalues were low in patients not displaying CAN in both
remain stable. The only clinical modification between thebiopsies, intermediate in patients showing either pro-
two protocol biopsies was a slight increase of proteinuriagression or regression of CAN and high in patients diag-
that, despite reaching statistical significance, was toonosed of CAN in both biopsies. Similarly, renal allograft
small to be considered of any clinical relevance. Duringsurvival was excellent in patients without CAN, interme-
this period of time, the CsA dose was tapered and accord-diate in patients in whom CAN apparently progressed
ingly CsA levels decreased. This modification may partlyor regressed, and poor in patients displaying CAN in
explain the lack of deterioration in renal function despiteboth biopsies (Table 6). Despite patients who progressed
the progression of renal scarring [18]. Together theseand patients who regressed showed a similar clinical evo-
results point out that the correlation between histologicallution, the probability to progress was higher than the
damage and clinical parameters in transplanted patientsprobability to regress (25% vs. 12%, P  0.05).
is not good enough to consider either renal function or
Clinical and histological variables associated with the proteinuria as a reliable marker of the progression of
progression of CAN CAN [6, 7, 15]. This observation reinforces the notion
that protocol biopsies allow information to be obtainedPatients were classified as progression or no progres-
sion of CAN. Progression of CAN was defined as the that is not contained in clinical data.
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Table 6. Serum creatinine (mol/L) and proteinuria (g/24 h) in the first and second protocol biopsy in patients displaying: both biopsies
without CAN, progression of CAN, regression of CAN and both biopsies with CAN
No CAN Progression Regression CAN in both biopsies P
N 54 39 19 43
1st biopsy
SCr 13131 14751 15848a 15844a 0.001
Proteinuria 0.220.12 0.310.17a 0.340.17a 0.390.28a 0.0003
2nd biopsy
SCr 12832 15148a 15137 16960a 0.0003
Proteinuria 0.180.12 0.290.22 0.380.42 0.710.85a,b,c 0.0001
Survival % 100 81.6 82.6 69.4 0.0020
Abbreviations are: CAN, chronic allograft nephropathy; SCr, serum creatinine.
a, b and c P  0.05 between that value and No CAN group, progression and regression groups respectively (Scheffe´ test)
Table 7. Clinical and histological characteristics of patients according to the progression of CAN between the first and second biopsies
No progression of CAN Progression of CAN P
N 104 51
First biopsy Banff scores
g-score 0.110.37 0.100.30 NS
i-score 0.710.76 0.670.68 NS
t-score 0.360.57 0.160.21 NS
v-score — —
ah-score 0.170.18 0.160.21 NS
cg-score 0.190.39 0.140.35 NS
ci-score 0.570.65 0.230.43 0.001
ct-score 0.570.68 0.250.44 0.001
cv-score 0.070.30 0.060.26 NS
N 102 48
Mean CsA dose at 1st biopsy 5.21.7 5.32.1 NS
Mean CsA dose between biopsies 4.01.3 4.21.8 NS
Mean CsA levels at 1st biopsy 21872 21774 NS
Mean CsA levels between biopsies 16550 14941 0.04
Cyclosporine (CsA) levels (ng/mL) were determined in 102 and 48 patients in the no progression of CAN and progression of CAN groups, respectively, since five
patients did not receive cyclosporine.
The severity of acute and chronic lesions observed in variability could account for some of these differences
[22].a renal compartment in the first biopsy correlated with
the same type of lesion in the same compartment in In a subset of patients diagnosed of CAN at four
months no chronic lesions were observed in the one-yearthe second biopsy. In contrast with the progression of
chronic lesions, acute lesions remained stable. In sequen- biopsy. This result raises the question whether apparent
regression of CAN reflects sampling error, intraobservertial protocol biopsies, Rush, Jeffery and Gough [10] and
Legendre et al [12] observed that acute lesions peak variability or a real regression of chronic damage. The
present study’s biopsies were evaluated according toduring the first few months and decrease thereafter,
while chronic lesions progress during the first year. In Banff criteria, which have been devised to evaluate diag-
nostic but not protocol biopsies. Despite that CAN rep-contrast, Nankivell et al showed that acute lesions peak
at three months while chronic lesions remain stable dur- resents a continuum, according to the Banff schema it
is diagnosed when tubular atrophy is present and intersti-ing the first year [19]. We previously observed that the
number of interstitial infiltrating cells assessed with tial fibrosis is observed in more than 5% of the biopsy
[3]. The extension of interstitial fibrosis and tubular atro-monoclonal antibodies decreased during the first year,
while acute lesions assessed with an ordinal scale appar- phy is used to grade CAN as mild (up to 25%), moderate
(26–50%) and severe (50%). In such a grading system,ently remained stable [20]. We did not find any correla-
tion between acute lesions in the early biopsy and chronic intra- and interobserver variability increases as the ex-
tension of damage approaches the cut-off separating twolesions in the second one, in contrast to other reports
[10, 14, 19, 21]. It is difficult to find a reasonable explana- categories. In the present study, the majority of patients
displayed either no CAN or grade I CAN. Accordingly,tion for these differences, but the timing of biopsies,
patient characteristics and immunosuppression were not in a proportion of biopsies, the degree of chronic damage
should have been in the cut-off separating both catego-the same in the different centers. Also, inter-observer
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ries. This notion is reinforced by the observation that was heterogeneous in the studied set of patients, but
graft survival was low in patients displaying CAN in both raises concern about a possible detrimental effect of low
biopsies, excellent in patients not displaying CAN in any cyclosporine levels during the first year [23].
biopsy, and intermediate in patients with progression or According to Banff schema an adequate sample must
regression of CAN. We interpret that in patients dis- contain at least ten glomeruli and two arteries. This con-
playing CAN in both biopsies, the degree of interstitial dition has been defined to properly diagnose acute rejec-
fibrosis and tubular atrophy was clearly over the thresh- tion but not CAN, since the distribution of acute lesions
old of 5% and in patients not displaying CAN in both is rather variable [3]. No relationship could be estab-
biopsies, no chronic lesions were present at all. In pa- lished between biopsy adequacy and the frequency distri-
tients with either apparent progression or regression, bution of the diagnosis of CAN, suggesting that the sam-
the degree of chronic lesions was around the cut-off
ple size requirement for a diagnosis of CAN may be less
separating CAN from no CAN, and accordingly the
than for acute rejection. This observation suggests thatprobability to misclassify such a pair of biopsies was the
even small samples can be considered viable to evaluatehighest.
the extension of chronic tubulointerstitial damage, espe-Progression of CAN was observed in 25% of patients
cially if they are evaluated by means of quantitativewhile regression was observed only in 12%, confirming
measures [11, 16, 24–26].that the probability to progress was higher than the prob-
The incidence of CAN progressed from 40 to 53%ability to regress. Approximately half of the patients who
during the study period in the overall group. This in-progressed displayed CAN grade II or III in the second
crease is relatively moderate if we take into considerationbiopsy while the other half displayed CAN grade I.
Nearly all patients with apparent regression displayed that the incidence of lesions that mimic CAN in blindly
CAN grade I in the first biopsy. Accordingly, this result evaluated donor biopsies at our center is 15% [15]. Thus,
suggests that apparent regression reflects the difficulty renal allograft scarring progresses rapidly during the first
to properly classify biopsies with mild interstitial fibrosis few months and slowly thereafter. This observation may
and tubular atrophy. have important implications in the design of trials aimed
The present data allow an evaluation of the accuracy to prevent renal scarring. In a trial in which progression
of Banff criteria to diagnose CAN in protocol biopsies. of scarring is evaluated by means of two sequential biop-
If we assume that during the study period real regression sies, the ideal timing of biopsies to reduce sample size
of scarring has not occurred, then 12% of the patients requirements will be defined according to the shortest
with apparent regression of CAN were misclassified. A
follow-up period in which the highest progression occurs.similar proportion of patients with progression to CAN
The present data do not favor the utilization of twomust also have been misclassified if we assume that the
protocol biopsies done during the first year, but suggestdistribution of sampling error follows a normal distribu-
that the best strategy to monitor progression of chroniction. Thus, in our hands the evaluation of protocol biop-
lesions is to perform a donor and a protocol biopsy dur-sies with Banff criteria implies a misclassification of ap-
ing the first year [15, 16].proximately 25% of the cases. This number represents
In summary, only a moderate increase in the incidenceboth sampling error associated with the performance of
and severity of CAN occurs between the 4 and 14 month.two sequential biopsies and intraobserver variability.
Despite the estimated error of 25% in the diagnosis of Moreover, in approximately 25% of biopsies the diagno-
CAN, we studied which clinical variables and histological sis of CAN is misclassified. Taken together, these data
lesions in the first biopsy were associated with the pro- suggest that evaluation of two sequential biopsies by
gression of CAN. Patients displaying less severe chronic means of the Banff schema is not the ideal strategy to
lesions at four months had a higher probability to pro- monitor progression of renal scarring. Thus, we suggest
gress. This result is probably a consequence of the grad- monitoring the progression of scarring by means of a
ing system employed. Mild progression of fibrosis in pa- donor and a protocol biopsy performed during the first
tients not displaying CAN in the first biopsy (interstitial year and evaluated with a quantitative approach.
fibrosis in less than 5% of biopsy surface) will result in
progression to CAN. On the contrary, in patients already
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